Magnitude of drug resistant shigellosis in Nepalese patients

Salman Khan¹, Priti Singh², Asnish Asthana³, Mukhtar Ansari⁴

¹Department of Microbiology, Nepalgunj Medical College, Nepal. ²Department of Biochemistry, Nepalgunj Medical College, Nepal. ³Department of Microbiology, Neta ji Subhash Chandra bose subharti Medical College, Swami Vivekanand Subharti University, India. ⁴Department of Pharmacology, National Medical College, Nepal.

Received: June 2013, Accepted: September 2013.

ABSTRACT

Background and Objectives: Shigella plays an important role as a causative organism of acute gastroenteritis, in children and others. Rapid emergence of antibiotic resistance warrants continuous monitoring of susceptibility pattern of bacterial isolates. We report here our findings about Shigella spp. isolates and their drug resistance patterns in Nepalese patients.

Materials and Methods: The study was conducted on 507 Nepalese patients with acute gastroenteritis attending outpatient and inpatient departments of Nepalgunj Medical college and teaching Hospital, Banke, Nepal from September 2011 to April 2013. Stool specimens were processed for isolation and identification of Shigella species following the standard microbiological methods while the disc diffusion test was used to determine antimicrobial resistance patterns of the recovered isolates at the central Laboratory of Microbiology.

Results: Sixty nine isolates were identified as Shigella species. S. flexneri, S. dysenteriae, S. boydii and S. sonnei accounted, respectively, for 42.03%, 27.54%, 21.74% and 8.70% of the total number of Shigella isolates. Resistance to nalidixic acid (95.65%), ampicillin (85.51%), co-trimoxazole (82.61%) and ciprofloxacin (47.83%) was observed. Among 69 isolates, 29 (42.03%) were from children aged 1-10 years and this group was statistically significant (P < 0.05), compared to the other age groups.

Conclusions: The study revealed endemicity of shigellosis with S. flexneri as the predominant serogroup in Nepalese patients. Children were at a higher risk of severe shigellosis. Nalidixic acid, ampicillin, co-trimoxazole and ciprofloxacin should not be used empirically as the first line drugs in treatment of shigellosis. Continuous local monitoring of resistance patterns is necessary for the appropriate selection of empirical antimicrobial therapy.

Keywords: gastroenteritis, Shigella, Antimicrobial resistance, Nepal.

INTRODUCTION

Shigellosis still remains a public-health problem in most developing countries where communities are ravaged by poverty, war, poor sanitation, personal hygiene, and water supplies (1). Epidemiological reports show that about 140 million people suffer from shigellosis with estimated 600,000 deaths per year worldwide (2, 3). They are four serogroups, Serogroup A: S. dysenteriae (12 serotypes), Serogroup B: S. flexneri (6 serotypes), Serogroup C: S. boydii (18 serotypes), Serogroup D: S. sonnei (1 serotype)(4). Shigella spp. is a major cause of dysentery/diarrhea in children and others. Many of them are hospitalized immediately after the onset of the disease. Though, oral rehydration is the principal tool of management, but, because of the enteroinvasiveness antibacterial treatment may be necessary (5). The emergence of antimicrobial resistance within members of the Enterobacteriaceae family is posing serious problems in the treatment of outbreaks of infections. Since its first report in studies

* Corresponding author: Salman Khan, Assistant professor Address: Department of Microbiology Nepalgunj medical college, Chisapani Banke, Nepal. Tel: +97-79848354981 E-mail: salman186631@gmail.com
conducted in the 1950s, multiple-drug resistance transmitted by plasmids among Shigella species has been reported from many countries (6-8). Moreover, an increase in resistance against many different drugs has been observed in the last two decades. In India, over 70% of Shigella isolates were resistant to two or more drugs including ampicillin and co-trimoxazole during 2002 to 2007 (9). Reports from Indonesia (10), Bangladesh (11), Malaysia (12), and Nepal (13) show increasing prevalence of Shigella isolates with multiple resistance to ampicillin, trimethoprim-sulphamethoxazole, tetracycline, and nalidixic acid. Similar resistance profiles have been also reported from Africa (14), Central America (15), Europe (16), and South America (17). Besides the temporal changes in the susceptibility patterns of Shigella species, it is well known that they may differ between geographical areas. Such differences are never stable and may change rapidly, especially in places where antibiotics are excessively used (particularly in developing countries) (18). This warrants for continuous monitoring of antibiotic susceptibility of this organism. This study was carried out to determine the antimicrobial resistance patterns of Shigella species in Nepalese patients.

MATERIALS AND METHODS

Study background and subjects. This was a prospective study conducted on 507 Nepalese patients with acute gastroenteritis, attending outpatients and inpatients departments of Nepalgunj Medical College and teaching Hospital, Banke, Nepal, between September 2011 and April 2013.

Sample collection and processing. Stool specimens were collected and processed following the standard microbiological methods (19) at the central Laboratory of Microbiology of Nepalgunj medical college and teaching hospital, Banke, Nepal. The specimens were inoculated on plates of Hektoen Enteric Agar, Salmonella-Shigella agar and deoxycholate citrate agar (Himedia Lab, Pvt Ltd, India). The plates were incubated at 37°C for 24 hours. The Shigella spp. isolates were speciated biochemically as outlined by Cowan (20) and confirmed by the slide agglutination test using polyvalent and monovalent antisera (Denka Seiken, Japan).

Antibiotic susceptibility testing. Antimicrobial sensitivity testing was determined by the Kirby-Bauer disc diffusion method (21) on Mueller Hinton agar (Himedia Lab, Pvt Ltd.) using the following antimicrobial agents: ampicillin (10 µg), cefotaxime (30 µg), ceftazidime (30 µg), ceftriaxone (30 µg), ciprofloxacin (5 µg), cotrimoxazole (25 µg), gentamicin (10 µg), imipenem (10 µg), nalidixic acid (30 µg) and ofloxacin (5 µg) (Himedia Lab, Pvt Ltd.). The plates were incubated at 37°C for 24 h, and the diameters of zone of inhibition were compared with those of the reference isolate (Escherichia coli ATCC 25922). Ethical approval for the study was taken from institutional research ethical committee.

Statistical analysis. Data obtained were analyzed using the SPSS (v. 18) Chicago, USA. Association of gender and age-groups with prevalence of Shigella spp. was assessed using chi-square test. P values <0.05 were considered to be statistically significant.

RESULTS

A total of 507 diarrheal/dysenteric stool samples were screened, Shigella spp. was identified in 69 (13.61%) samples. The prevalence of S. flexneri was identified in 29 isolates (42.03%), while S. dysenteriae in 19 (27.54%), S. boydii in 15 (21.74%) and S. sonnei in 6 (8.70%) of the total number of isolates (Table 1). S. flexneri has been the predominant isolate during the period of the study. Among 69 positive sample, 38 (55.07%) were male (Table 2). Shigella spp. were isolated from patients aged between 1 and > 60 years. A high prevalence (42.03%) was identified in subjects aged 1-10 years and this age group was statistically significant (P <0.05) compared to the other age groups. However, there was no significant difference in the overall prevalence of isolates according to sex. The resistance pattern of Shigella spp. isolated between September 2011 to April 2013 is as shown in Table 3. Over 80% of Shigella isolates were resistant to 2 or more drugs including ampicillin, nalidixic acid and co-trimoxazole. All the isolates recovered from the age group 51 - 60 and > 60 were resistant to these drugs. The maximum resistant isolates were observed in 1 -10 age group. Resistance rate to nalidixic acid was 95.64%, ampicillin 85.51%, co-trimoxazole 82.61%, ciprofloxacin 47.83%, gentamicin 24.64%, ceftriaxone 24.64%, ofloxacin 21.74%, ceftazidime 18.84%, cefotaxime 15.94%. No resistance was observed to imipenem during the study period.
Shigellosis still accounts for a significant proportion of morbidity and mortality, especially in developing countries (22). The majority of the Shigella strain were isolated from children aged 1-10 years, according with previous studies (9, 22, 23). The changing patterns in the distribution of Shigella serogroups and serotypes have been reported from time to time (24-26). The shift in the prevalence of serogroups and serotypes could be attributed to geographic, socio-demographic, climatic and environmental differences.

Over the past decades, a significant number of Shigella isolates resistant to commonly-prescribed antimicrobials have been reported (30). In early 1990s, many isolates were susceptible to nalidixic acid, norfloxacin, furazolidone, and gentamicin (25, 29). In the late 1990s, most isolates, showed an increased resistance to these antimicrobials (24, 31) but most were susceptible to ciprofloxacin (13, 32, 33). In the present study, an overall high rate of resistance was observed to ampicillin, nalidixic acid and co-trimoxazole. Of interest, all the isolates recovered from the age group 51-60 and >60 were resistant to these drugs. The maximum resistant isolates were observed in 1-10 age group, which was more or less similar to some studies conducted in India, Iran, Ethiopia and Nigeria (9,27,34-36). In addition, these isolates, resistant to ciprofloxacin, showed a trend towards an increased incidence of resistance, especially in S. dysenteriae and S. flexneri during the study period. Although fluoroquinolones are recommended as the drugs of choice for shigellosis by World Health Organization (37), emergence of fluoroquinolone resistance among Shigella spp. has now been documented in many countries (38-40). At present, alternative drugs such as the third generation cephalosporins are being commonly used. However, the present study shows that Shigella strains are rapidly acquiring resistance to these drugs as well. The emergence of plasmid borne resistance to cephalosporins further reduces the therapeutic option for the treatment of shigellosis. The genetic transfer of drug resistance genes may not be of immediate concern for the treating clinicians, but will pose a potential problem in the future. Their presence, along with the potential for plasmid mediated quinolone resistance, will be surely create significant therapeutic problems in the future. Widespread selective pressure

Table 1. Distribution of Shigella spp. recovered from different age groups.

| Shigella species | 0-10 | 11-20 | 21-30 | 31-40 | 41-50 | 51-60 | >60 | Total |
|-----------------|------|-------|-------|-------|-------|-------|-----|-------|
| Shigella flexneri | 14   | 5     | 6     | 2     | 1     | -     | 1   | 29 (42.03) |
| Shigella dysenteriae | 9    | 4     | 5     | -     | 1     | -     | -   | 19 (27.54) |
| Shigella boydii | 5    | 2     | 4     | 3     | -     | -     | 1   | 15 (21.74) |
| Shigella sonnei | 1    | 1     | 1     | 1     | 1     | -     | 1   | 5 (7.39) |
| Total | 29   | 12    | 16    | 6     | 3     | 1     | 2   | 69 (100) |

Considering resistance patterns in the different serogroups, S. boydii showed 100% resistance to nalidixic acid and co-trimoxazole; S. sonnei was 100% resistant to ampicillin, 83.33% to co-trimoxazole and nalidixic acid; S. flexneri showed 96.55% resistance to nalidixic acid and ampicillin and S. dysenteriae showed most frequently resistance to nalidixic acid (94.74%) and co-trimoxazole (84.21%).

DISCUSSION

Table 2. Distribution of Shigella spp. by gender.

| Shigella species | Male | Female | Total No (%) |
|-----------------|------|--------|--------------|
| Shigella flexneri | 16   | 13     | 29 (42.03)   |
| Shigella dysenteriae | 10   | 9      | 19 (27.54)   |
| Shigella boydii | 8    | 7      | 15 (21.74)   |
| Shigella sonnei | 4    | 2      | 6 (8.70)     |
| Total | 38   | 31     | 69 (100)     |

could be attributed to geographic, socio-demographic, climatic and environmental differences.
and efficient dissemination routes for multi drug resistant organisms are major factors contributing to the rapid emergence and spread of drug resistant organisms.

CONCLUSION

The emergence of resistance to many drugs, such as fluoroquinolones and third generation cephalosporins, in Shigella is a cause of great concern not only at local and regional level, but also in a national and international scale. The culture of antimicrobial abuse needs to be soon stopped. Continuous surveillance of multidrug resistant strains is very important to know the changing antibiotic susceptibility patterns as well as the cyclical changes of the serogroups from time to time because the resistance patterns are related to the serogroup. A network of laboratories for real time monitoring of antibiotic resistance of Shigella and timely dissemination of such information to the clinicians for modification of treatment strategy are urgently necessary.

ACKNOWLEDGEMENTS

The authors are grateful to the Managing Director of Nepalgunj Medical College, Nepal for administrative support.

REFERENCES

1. Shears P. Shigella infections. Ann Trop Med Parasitol 1996; 90: 105-114.
2. World Health Organization. Vaccine research and development: new strategies for accelerating Shigella vaccine development. Wkly Epidemiol Rec 1997; 72: 73-80.
3. World Health Organization. Diarrhoeal disease due to Shigella disease. In: Vaccines, immunization and biologicals. Geneva: World Health Organization, 1998: 1-5
4. Handin RI (1998). Shigellosis. In: Gerald TK, Dennis JK- Harrison’s Principles of Internal Medicine, Vol-1, 14th ed. New York: Mc Graw Hill Inc, PP. 957-959.
5. Iwalokun BA, Gbenle GO, Smith SI, Ogunledun A, Akinsinde KA, Omonigbehin EA. Epidemiology of Shigella flexneri and Shigella sonnei in Lagos, Nigeria: trends in antimicrobial resistance. J Health Popul Nutr 2001; 19: 183-90.
6. Geo FB, Janet SB, Stepehn AM. Jawetz, Melnick, Adelberg’s (1998). Medical Microbiology, 21st ed. Appleton & Lange publishers, PP. 224-226.
7. Guyot A. Antibiotic resistance of Shigella in Monorovia, Liberia. J Trop Doc 1969; 26: 70-71.
8. Brito A, Nij B. Antibiotic resistance pattern and plasmid profiles for Shigella spp. isolated in Cordoba, Argentina. J Antimicrob Chemother 1994; 34: 253-259.
9. H Srinivasa, M Bajayanti, Y Raksha. Magnitude of drug resistant shigellosis: A report from Bangalore. Indian Journal of Medical Microbiology 2009; 27: 358-360.
10. Subekti D, Oyoo BA, Tjaniadi P, Corwin AL, Larasati W, Putri M et al. Shigella spp. surveillance in Indonesia: the emergence or reemergence of S. dysenteriae. Emerg Infect Dis 2001; 7: 137-140.
11. Shahid NS, Rahaman MM, Haider K, Banu H, Rahman N. Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh. J Infect Dis 1985; 152: 1114-119.
12. Thong KL, Hoe CH, Koh YT, Yasim RM. Prevalence of multidrug-resistant Shigella isolated in Malaysia. J Health Popul Nutr 2002; 20: 356-8.
13. Wilson G, Easow JM, Mukhopadhyay C, Shivananda PG. Isolation and antimicrobial susceptibility of Shigella from patients with acute gastroenteritis in Western Nepal. Indian J Med Res 2006; 123: 145-150.
14. Bogaerts J, Verhaegen J, Munyabikali JP, Mukantabana
Khan ET AL.

B, Lemmens P, Vandeven J. Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increased frequency of multiple resistance. *Diagn Microbiol Infect Dis* 1997; 28: 165-171.

15. Mata LJ, Gangojroja EJ Caceres A, Perera DR, Mejicanos ML. Epidemic *Shiga* bacillus dysentery in Central America. 1. Etiologic investigations in Guatemala, 1969. *J Infect Dis* 1970; 122: 170-180.

16. Essers B, Burns AP, Lanfranchini FM, Somaruga SG, von Vigier RO, Schaad UB et al. Acute community-acquired diarrhea requiring hospital admission in Swiss children. *Clin Infect Dis* 2000; 31: 192-196.

17. Torres ME, Pirez MC, Schelotto F, Varela G, Parodi V, Allende F et al. Etiology of children’s diarrhea in Montevideo, Uruguay: associated pathogens and unusual isolates. *J Clin Microbiol* 2001; 39: 2134-2139.

18. Leslie C, Albert B, Max S (1998). *Escherichia* and *Shigella*. In: Topley & Wilson’s Microbiology and Microbial Infections, 9th ed. Arnold Press, Great Britain. 948-50.

19. Niyogi SK. Shigellosis. *J Microbiol* 2005; 43: 33-43.

20. Cowan ST. (1974) Manual for identification of medical bacteria. 2d ed. London: Cambridge University Press, PP. 104-105.

21. Bauer AW, Kirby WMM, sherris JC, Turk M. Antibiotic susceptibility testing by a standard single disc method. *Am J Clin Pathol* 1966; 45: 493-496.

22. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swordlow DL, Sansonetti PJ et al. Global burden of *Shigella* infections: implications for vaccine development and implementation of control strategies. *Bull World Health Organ* 1999; 77: 651-666.

23. Bhattacharyya S, Basudha Khanal S, Bhattacharji N R, Das. Prevalence of *Shigella* species and their antimicrobial resistance patterns in Eastern Nepal. *J health popul nutr* 2005; 23: 339-342.

24. Niyogi SK, Mitra U, Dutta P. Changing patterns of serotypes and antimicrobial susceptibilities of *Shigella* species isolated from children in calcutta,India. *Jpn J Infect Dis* 2001; 54: 121-122.

25. Jesudason MV. *Shigella* isolation in Vellore, South India (1997-2001). *Indian J Med Res* 2002; 115: 11-13.

26. Zaman K, Yunus M, Baqui AH, Hossain KMB. Surveillance of shigellosis in rural Bangladesh: a 10 years review. *J Pak Med Assoc* 1991; 41: 75-78.

27. Bhattacharyya D, Sugunan AP, Bhattacharjee H, Thamizhmani R, Sayi DS, Thanasekaran, et al. Antimicrobial resistance in *Shigella* - rapid increase & widening of spectrum in Andaman Islands, India. *Indian J Med Res* 2012; 135: 365-370.

28. Shrestha CD,Malla S, Maharjan L. Multi drug resistant *Shigella* species in Nepal, a retrospective study conducted at National Public Health Laboratory (NPHEL),1999 to 2002. *J Nepal Health Res Coun* 2002; 4: 365-370.

29. Thapa BR, Ventkateswarlu K, Malik AK, Panigrahi D. Shigellosis in children from North India: a clinicopathological study. *J Trop Pediatr* 1995; 41: 303-307.

30. Bennish ML, Salam MA, Hossain MA, Myaux J,Khan EH, Chakraborty J et al. Antimicrobial resistance of *Shigella* isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. *Clin Infect Dis.* 1992; 14: 1055-1060.

31. Sack BR, Rahman M, Yunus M, Khan HE. Antimicrobial resistance in organisms causing diarrheal disease. *Clin Infect Dis* 1997; 24: 102-105.

32. Khan AI, Huq S, Malek MA, Hossain MI, Talukder KA, Faruque ASG et al. *Shigella* serotypes among hospitalized patients in urban Bangladesh and their antimicrobial resistance. *Epidemiol Infect* 2004; 132: 773-777.

33. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind,randomized, controlled trial. *Ann Intern Med* 1997; 126: 697-703.

34. Gharibi O, Zangene N, Mohammad N, Mirzaei K, Karimi A, Gharibi A, et al. Increasing antimicrobial resistance among *Shigella* isolates in the Bushehr, Iran. *Pak J Biol Sci* 2012; 15: 156-159.

35. Gizachew Y, Challu N, Afework K. A five-year antimicrobial resistance pattern observed in *Shigella* species isolated from stool samples in Gondar University Hospital, northwest Ethiopia. *Ethiop J Health Dev* 2006; 20: 194-198.

36. Iwalokun BA, Gbenle GO, Smith SI, Ogunledun A, Akinsinde KA, Omonigbehin EA. Epidemiology of Shigellosis in Lagos, Nigeria:Trends in Antimicrobial Resistance. *J Health Popul Nutr* 2001; 19: 183-190.

37. Guidelines for the Control of Shigellosis, including epidemics due to *Shigella dysenteriae* type1.Geneva: WHO; 2005.[accessed on September 22, 2010].

38. Naheed A,Kalluri P,Talukder KA, Faruque AS, Khatun F, Nair GB et al. Fluoroquinolone & resistant *Shigella dysenteriae* type 1 in northeastern Bangladesh. *Lancet Infect Dis* 2004; 4: 607-608.

39. Hirose K, Terajima J, Izumiya H, Tamura K, Arakawa E, Takai N, et al. Antimicrobial susceptibility of *Shigella sonnei* isolates in Japan and molecular analysis of *S. sonnei* isolates with reduced susceptibility to fluoroquinolones. *Antimicrob Agents Chemother* 2005; 49: 1203-1205.

40. Roy S, Bhattacharyya D, Thanasekaran K, Ghosh AR, Manimunda SP, Bharadwaj AP, et al. Emergence of fluoroquinolone resistance in *Shigella* isolated from Andaman & Nicobar Islands, *India. Indian J Med Res* 2010; 131: 720-722.